The workshop will bring together leading institutional and angel investors with early-stage science-based companies that are investment grade and preparing for their first or subsequent institutional rounds of financing. Participating companies must be commercializing technology that falls broadly in two areas emphasizing molecular science: 1) life sciences and biomedical, including for example diagnostic tests, therapeutics, and some medical devices, and 2) physical sciences, such as applications of nanoscience to clean energy and new materials. Overlaps between the two areas, such as using novel materials in medical devices or nanoparticles as drug delivery agents, are also desirable. In either area preference is for companies whose technologies are based on fundamental scientific breakthroughs that can enable the creation of first-in-class products addressing significant unmet needs in our society.
Morning sessions will include one presentation from an investor on investment topics that are educational to the companies and presentations by up to two companies. In the spirit of the early Telluride Workshops, the format will include longer (and within reason untimed!) presentations than the typical 15-30 min investment pitches. This will encourage a deep dive into each company's technology and business plan and allow time for discussion.
A key element of the workshop is enabling multiple interactions between the investors and teams of entrepreneurs in different settings inside or outside of the meeting room to allow the formation of deeper interpersonal relationships and bonds. To that effect the afternoons and evenings will include both free time as well as group events (hikes, dinners, events organized by TSRC, etc...) aimed to foster such relationships. Many past workshop participants bring their families to Telluride.
Another key element is to expose the participating companies to the thought process of a diverse group of investors with different backgrounds such as they might encounter during their fundraising.
For investors the workshop will provide an opportunity to give back to the entrepreneurial community by sharing their expertise with emerging young companies and providing candid feedback that will help them to improve their business plan and strategy. They will learn about quality companies that might be of future investment interest. Investors would also be able to interact with leading researchers from around the world taking part in concurrent workshops (such as metabolomics and chromatin structure) in areas of science that are likely to emerge as new investment frontiers.
Early-stage company founders and management will benefit from establishing relationships and receiving guidance and advice from experienced investors that will candidly share how they approach the evaluation of investment opportunities. Each team will be able to interact with the investors multiple times over the course of the workshop and thus receive comprehensive input not only during its formal presentation, but also through informal interactions as well as by participating in the discussions of the presentations of the other companies.
Participation will be limited to approximately five investors and up to ten companies, each desirably represented by one scientist and one key management team member.
Invitee List of Investor Participants
1) Thomas Blum, MBA, is an investment banker currently at G.C. Andersen Partners, and previously at Salomon Brothers and Bear Sterns. He has served as Managing Director and Partner at private equity and venture capital firms Columbia Financial Partners and Channel Capital, and is an angel investor with New York Angels.
2) Faz Bashi, MD is an active angel investor, Board Member of the Angel Capital Association, and has chaired the Medical Devices and Digital Health committees of Life Science Angels. He is the lead venture partner of the Femtech fund Portfolia.
3) Marc Goldberg, JD, MBA is managing partner and founder of BioVentures Investors - a life science venture capital fund based in MA with over $200 assets undermanagement across four funds with a current focus on medical devices and diagnostic tests. Previously he founded the Massachusetts Biotechnology Council.
4) Kevin Morningstar, MBA, is a partner with Rockies Venture Fund in Denver, an angel investor with the Rockies venture club, and runs a consulting firm in the medical device industry.
5) Pratik Shah, PhD, MBA, was most recently the CEO of Auspex, a public company acquired by Teva Pharmaceuticals in 2016 for $3.5B that developed a deuterated drug for treating the effects of Huntingonâs Disease. Previously he was a partner at the leading life science venture capital firm Thomas McNerney and Partners and co-founder of Kalypsis.
6) Elaine Heron, PhD, MBA, is presently on the Boards of BioMarin Pharmaceuticals(NASDAQ:BMRN), Amplyx Pharmaceuticals, and Vala Sciences. She was formerly General Manager of a $1B Perkin-Elmer division for DNA synthesis and sequencing, PCR, and arrays, and vice-president at Affymetrix. She is an active member of Life Science Angels.
7) Sam Guren, MBA, is currently a strategic advisor to OCA Ventures in Chicago. He was formerly at William Blair where he co-founded and managed three William Blair Venture Partners funds and at Robert Baird where he managed the Baird Capital Funds. He was also a managing director of Hyde Park Angels.
8) Keith Crandell, MBA, MS, is a general partner with Arch Venture Partners which he founded in 1988. Arch has managed over $1B in assets over nine funds and is focused on science research-based technologies in the life and material sciences.
9) Pete McNerney, MBA, is presently on the faculty of the Kellogg School of Business at Northwestern University. After an 11-year career at Baxter in general management positions internationally he co-founded Coral Ventures in 1992, and subsequently Thomas McNerney and Partners â life sciences venture capital funds that achieved top decile returns.
10) Konstantin Kostov, PhD, is an angel investor with Life Science Angels and Cantina Angels, a group that he co-founded. He first attended the Telluride Workshops in 1998 by virtue of being a postdoctoral fellow in the research group of their co-founder, R. Stephen Berry, at the University of Chicago; and has been coming back to Telluride ever since.
Workshop Price: $ 490.00
Early Bird Lodging Discount Available Until: 06/15/2019
A $100.00 discount is applied to your lodging cost when you register before 06/15/2019.
All cancelled registrations are subject to a $100 Cancellation Fee. TSRC can only guarantee a refund for the balance of fees and lodging charges paid when a refund is requested prior to the Cancellation Deadline that is specific to each workshop, which in this case is 06/22/2019. TSRC always recommends that participants purchase travel insurance to protect against unforeseen, last-minute travel plan changes.